SLC35E3 is a putative nucleotide-sugar transporter belonging to solute carrier family 35, localized to the Golgi membrane and endoplasmic reticulum with annotated nucleotide-sugar transmembrane transporter and antiporter activities 1. While SLC35B1 serves as the primary transporter of UDP-glucuronic acid (UDPGA) into the endoplasmic reticulum for glucuronidation, SLC35E3 knockdown also decreased glucuronosyltransferase activity in HEK293 cells expressing UGT1A1, suggesting a supplementary role in UDPGA transport, though this effect was not observed in HepaRG hepatocytes 1. SLC35E3 dysfunction is implicated in defective glyco-conjugation in the Golgi complex and/or endoplasmic reticulum 2. Clinically, SLC35E3 dysregulation is associated with multiple pathologies: it is targeted by upregulated miRNA (novel-m1061-5p) in cardiovascular disease patients 2, shows genomic amplification and overexpression in glioblastoma multiforme 3, is co-amplified with MDM2 and CPM in intimal sarcomas 4, and carries enriched coding variants associated with inflammatory bowel disease risk in French-Canadian populations 5. These findings suggest SLC35E3 plays context-dependent roles in nucleotide-sugar homeostasis with relevance to multiple malignancies and inflammatory conditions.